Intarcia
is a pharmaceutical company that develops and commercializes novel therapeutics for the treatment of chronic diseases... Read moreIntarcia
is a pharmaceutical company that develops and commercializes novel therapeutics for the treatment of chronic diseases... Read more
News
Aug 30, 2023
BioPharma Dive
Intarcia: Intarcia, a former biotech unicorn, gets new life with startup deal
Aug 29, 2023
The Business Journals
Intarcia: Embattled Intarcia drug licensed to Harvard spinout, with Intarcia CEO Kurt Graves at the helm
Aug 29, 2023
Endpoints News
Intarcia: i2o Therapeutics closes $46M Series A, names Kurt Graves as CEO and acquires Intarcia's diabetes asset
Aug 25, 2023
PharmaLeaders
Intarcia: Implantable Diabetes Drug-Device Combo From Intarcia Gets Public Hearing
Aug 23, 2023
Endpoints News
Intarcia: FDA advisory committee will meet in September to discuss Intarcia's diabetes drug
Mar 28, 2023
Endpoints News
Intarcia: FDA plans upcoming adcomms for OTC contraceptive, epinephrine nasal spray, Intarcia's last shot
Feb 09, 2023
BioPharma Dive
Intarcia: FDA offers former biotech unicorn Intarcia a chance for a panel review
Mar 25, 2022
Endpoints News
Intarcia: Intarcia may finally get its post-CRL review, although FDA points to Covid and another hearing as taking priority
Dec 28, 2020
Yicai Global
Intarcia: China VC Luxin Warns of USD21.4 Million Loss as Its US Biopharma Firm Intarcia Winds Up
Mar 12, 2020
The Pharma Letter
Intarcia: Diabetes drug-device combo rejected again
Intarcia Competitors
1
2
3
4
5
6
7
8
9
10